Oct 07, 2021 / 12:30PM GMT
Operator
Good day, and welcome to the RedHill Biopharma's webcast on the opaganib Phase II/III data. (Operator Instructions)
At this time, I would like to introduce to the conference call RedHill's CEO, Dror Ben-Asher; Gilead Raday, RedHill's Chief Operating Officer; and Dr. Mark Levitt, RedHill's Medical Director Oncology.
Before we begin, we will read from RedHill's safe harbor statement. Please go ahead.
Alexandra Okmian - RedHill Biopharma Ltd. - Senior Business Development & IR Manager
This conference call may contain projections or other forward-looking statements regarding future events or the future performance of RedHill, including statements with respect to the business promotion and other efforts related to RedHill's commercialization activities and the initiation, timing, progress and results of RedHill's research, manufacturing, preclinical studies, clinical trials, marketing applications and approvals, if any, including the results and the clinical study of opaganib for the treatment of COVID-19.
These statements are only
Redhill Biopharma Ltd To Discuss The Opaganib Phase 2/3 COVID-19 Data Call Transcript
Oct 07, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers